Content
Search
Navigation
Sitemap
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chief Executive, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Sustainability
Sustainability policies
20.06.22
Climate ambition statement
PDF (0.08Mb)
20.06.22
Modern Slavery Statement
PDF (0.18Mb)
17.06.21
Approach to Taxation
PDF (0.12Mb)
17.06.21
Responsible Investment Policy
PDF (0.13Mb)
17.06.21
Sustainability Policy
PDF (0.27Mb)
Close menu
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chief Executive, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search